|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00573521 |
|
Date of registration:
|
12/12/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
|
|
Scientific title:
|
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms |
|
Date of first enrolment:
|
November 2007 |
|
Target sample size:
|
450 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00573521 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Retrospective
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Brian Potoski, Pharm D |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Pittsburgh |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Clinical information is collected by chart review of "case" and "control" patients.
- A "case A" patient is defined as follows: One or more clinical cultures are positive
for an ESBL producing bacteria and the organism is piperacillin/tazobactam resistant.
- A "case B" patient is defined as follows: One or more clinical cultures are positive
for an ESBL producing bacteria and the organism is piperacillin/tazobactam
susceptible.
- Additionally, 1 control patient in the hospital at the same time as the case patients
will be randomly selected for each case and are not in either case group.
Exclusion Criteria:
- Patients < 18 years of age
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Enterobacteriaceae Infections
|
|
Primary Outcome(s)
|
|
This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients.
[Time Frame: 2 years]
|
|
Secondary ID(s)
|
|
PRO07100136
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|